| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $51,784,015 | 54 | 100 |
| Hughes Steven George | Chief Medical Officer | 0 | $0 | 2 | $410,347 | $-410,347 |
| Gallagher Kathleen P. | Chief Program Officer | 0 | $0 | 6 | $839,117 | $-839,117 |
| Thompson Tamar | director | 0 | $0 | 1 | $1.35M | $-1.35M |
| LEVIN ARTHUR A | director | 0 | $0 | 9 | $5.1M | $-5.1M |
| McCarthy Teresa | Chief Human Resources Officer | 0 | $0 | 9 | $5.74M | $-5.74M |
| MacLean Michael F | Chief Financial Officer | 0 | $0 | 7 | $7.26M | $-7.26M |
| Flanagan W. Michael | CSTO | 0 | $0 | 9 | $11.38M | $-11.38M |
| Boyce Sarah | President and CEO | 0 | $0 | 11 | $19.71M | $-19.71M |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Avidity Biosciences, Inc. have bought $0 and sold $51.78M worth of Avidity Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Avidity Biosciences, Inc. have bought $18.45M and sold $13.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 800,000 shares for transaction amount of $14.4M was made by RTW INVESTMENTS, LP (10 percent owner) on 2021‑08‑04.
| 2025-05-01 | Sale | Gallagher Kathleen P. | Chief Program Officer | 5,875 0.0048% | $32.40 | $190,324 | -9.40% | |
| 2025-04-01 | Sale | Gallagher Kathleen P. | Chief Program Officer | 329 0.0003% | $27.83 | $9,155 | +9.20% | |
| 2025-03-20 | Sale | Boyce Sarah | President and CEO | 31,540 0.0264% | $31.06 | $979,563 | -4.25% | |
| 2025-03-20 | Sale | McCarthy Teresa | Chief Human Resources Officer | 7,778 0.0065% | $31.06 | $241,583 | -4.25% | |
| 2025-03-20 | Sale | MacLean Michael F | Chief Financial Officer | 7,935 0.0066% | $31.06 | $246,425 | -4.25% | |
| 2025-03-20 | Sale | Flanagan W. Michael | Chief Scientific Officer | 11,780 0.0099% | $31.06 | $365,868 | -4.25% | |
| 2025-03-20 | Sale | Hughes Steven George | Chief Medical Officer | 9,578 0.008% | $31.06 | $297,491 | -4.25% | |
| 2025-03-11 | Sale | Flanagan W. Michael | Chief Scientific Officer | 20,000 0.0169% | $30.13 | $602,614 | +1.15% | |
| 2025-03-03 | Sale | Gallagher Kathleen P. | Chief Program Officer | 5,875 0.005% | $29.41 | $172,807 | +2.40% | |
| 2025-02-03 | Sale | Gallagher Kathleen P. | Chief Program Officer | 5,875 0.0048% | $32.16 | $188,918 | -4.69% | |
| 2025-01-22 | Sale | Gallagher Kathleen P. | Chief Program Officer | 5,629 0.0047% | $30.16 | $169,776 | +1.33% | |
| 2025-01-21 | Sale | Boyce Sarah | President and CEO | 10,397 0.0081% | $28.59 | $297,291 | -1.20% | |
| 2025-01-21 | Sale | McCarthy Teresa | Chief Human Resources Officer | 2,959 0.0023% | $28.59 | $84,612 | -1.20% | |
| 2025-01-21 | Sale | MacLean Michael F | Chief Financial Officer | 3,287 0.0026% | $28.59 | $93,985 | -1.20% | |
| 2025-01-21 | Sale | Flanagan W. Michael | Chief Scientific Officer | 5,672 0.0044% | $28.60 | $162,192 | -1.20% | |
| 2025-01-21 | Sale | Hughes Steven George | Chief Medical Officer | 3,947 0.0031% | $28.59 | $112,856 | -1.20% | |
| 2025-01-21 | Sale | Gallagher Kathleen P. | Chief Program Officer | 3,782 0.0029% | $28.59 | $108,136 | -1.20% | |
| 2025-01-21 | Sale | LEVIN ARTHUR A | director | 1,872 0.0015% | $28.60 | $53,537 | -1.20% | |
| 2024-12-18 | Sale | Boyce Sarah | President and CEO | 31,855 0.0283% | $32.66 | $1.04M | -0.75% | |
| 2024-12-18 | Sale | MacLean Michael F | Chief Financial Officer | 11,151 0.0099% | $32.66 | $364,192 | -0.75% |
| Boyce Sarah | President and CEO | 305871 0.2538% | $9.35M | 0 | 22 | |
| McCarthy Teresa | Chief Human Resources Officer | 97130 0.0806% | $2.97M | 0 | 10 | |
| MacLean Michael F | Chief Financial Officer | 96720 0.0802% | $2.96M | 0 | 10 | |
| Flanagan W. Michael | Chief Scientific Officer | 80195 0.0665% | $2.45M | 0 | 10 | |
| Hughes Steven George | Chief Medical Officer | 72850 0.0604% | $2.23M | 0 | 2 | |
| Gallagher Kathleen P. | Chief Program Officer | 50554 0.0419% | $1.55M | 0 | 6 | |
| LEVIN ARTHUR A | director | 12958 0.0108% | $396,255.64 | 0 | 28 | |
| Thompson Tamar | director | 0 0% | $0 | 0 | 1 | |
| RTW INVESTMENTS, LP | 10 percent owner | 4795000 3.978% | $146.63M | 2 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 2514545 2.0861% | $76.89M | 1 | 0 | <0.0001% |
$52,263,649 | 70 | 1.18% | $4.87B | |
$42,463,802 | 57 | 17.85% | $3.72B | |
$1,275,975,557 | 32 | 19.44% | $3.68B | |
$62,927,079 | 29 | 14.02% | $3.87B | |
$103,944,213 | 17 | 5.95% | $3.97B | |
$11,859,102 | 17 | 18.62% | $3.65B | |
$1,279,017 | 16 | 51.12% | $5.17B | |
$128,181,928 | 16 | 18.84% | $3.82B | |
$74,605,681 | 14 | 47.06% | $3.18B | |
$57,686,748 | 13 | 21.11% | $3.64B | |
$177,517,505 | 13 | 16.65% | $3.7B | |
$2,477,801 | 11 | 4.98% | $4.84B | |
$11,898,979 | 10 | 54.58% | $3.61B | |
$1,711,150 | 9 | 31.59% | $3.03B | |
$4,623,072 | 7 | 11.07% | $3.37B | |
$182,500,000 | 6 | 29.00% | $3.52B | |
$14,400,000 | 5 | 41.34% | $3.5B | |
$41,376,000 | 4 | -12.07% | $4.2B | |
Avidity Biosciences, Inc. (RNA) | $36,900,000 | 3 | -9.12% | $3.69B |
| Increased Positions | 131 | +50.78% | 17M | +12.41% |
| Decreased Positions | 114 | -44.19% | 15M | -11.1% |
| New Positions | 34 | New | 3M | New |
| Sold Out Positions | 48 | Sold Out | 8M | Sold Out |
| Total Postitions | 275 | +6.59% | 136M | +1.31% |
| Fmr Llc | $531,609.00 | 13.76% | 16.51M | -339,170 | -2.01% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $355,579.00 | 9.2% | 11.04M | +408,861 | +3.85% | 2024-12-31 |
| Blackrock, Inc. | $319,343.00 | 8.27% | 9.92M | -14,895 | -0.15% | 2025-03-31 |
| Vanguard Group Inc | $303,708.00 | 7.86% | 9.43M | +205,027 | +2.22% | 2024-12-31 |
| Wellington Management Group Llp | $261,016.00 | 6.76% | 8.11M | +1M | +15.29% | 2024-12-31 |
| Rtw Investments, Lp | $255,438.00 | 6.61% | 7.93M | -200,000 | -2.46% | 2024-12-31 |
| Avoro Capital Advisors Llc | $241,500.00 | 6.25% | 7.5M | +625,000 | +9.09% | 2024-12-31 |
| Janus Henderson Group Plc | $227,107.00 | 5.88% | 7.05M | +2M | +44.05% | 2024-12-31 |
| Ra Capital Management, L.P. | $202,873.00 | 5.25% | 6.3M | 0 | 0% | 2024-12-31 |
| State Street Corp | $148,191.00 | 3.84% | 4.6M | -103,915 | -2.21% | 2024-12-31 |